Personalised Cancer Vaccines Hit a Landmark: Moderna and Merck Trial Meets Phase 3 Endpoints

A Phase 3 clinical trial of intismeran, a personalised mRNA cancer vaccine developed by Moderna and Merck, met both its primary endpoints — significantly extending the time melanoma patients remained cancer-free and preventing the disease from spreading to other organs. The trial, called INTerpath-001, enrolled 1,137 high-risk melanoma patients whose tumours had been surgically removed and genetically sequenced. The treatment pairs Merck's blockbuster...